HealthBiotech, pharma, medical devices and FDA news.HealthSenhwa Completes Enrollment in Phase 1b CX-5461 Expansion Trial; CSR Expected in Q1 2027Senhwa Biosciences, Inc. · August 25, 2026HealthAntengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune DiseasesAntengene Corporation Limited · August 25, 2026HealthAstellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinomaAstellas Pharma Inc. · August 24, 2026HealthFDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patientsJohnson & Johnson · August 24, 2026
HealthSenhwa Completes Enrollment in Phase 1b CX-5461 Expansion Trial; CSR Expected in Q1 2027Senhwa Biosciences, Inc. · August 25, 2026
HealthAntengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune DiseasesAntengene Corporation Limited · August 25, 2026
HealthAstellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinomaAstellas Pharma Inc. · August 24, 2026
HealthFDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patientsJohnson & Johnson · August 24, 2026
